Aarvik Therapeutics Welcomes Laurus Labs as Strategic Investor

• Aarvik Therapeutics has received an investment from Laurus Labs, India, as part of its recently completed Series Seed 2 financing round.

• The funding will support further development of Aarvik’s proprietary MUTTA™ platform and its pipeline of next-generation antibody-drug conjugates (ADCs).

Aarvik Therapeutics, an antibody-drug conjugate (ADC) biotechnology company, has secured investment from Laurus Labs, India, in its Series Seed 2 financing round. The funding, which also included multiple other investors, will support the advancement of Aarvik’s ADC pipeline.

Since its launch in 2021, Aarvik has developed the MUTTA™ (MUlti-epitope Targeting Tetravalent Antibody) platform. The platform is designed to expand ADC therapy beyond a limited set of targets while improving the therapeutic window by lowering the minimum effective dose (MED) and maintaining or increasing the maximum tolerated dose (MTD).

“As part of our global support of innovation and progress in healthcare, we are delighted to invest in Aarvik’s efforts to pursue breakthroughs in oncology therapies. We look forward to a highly productive collaboration that results in tangible benefits for patients across the globe.”

Dr. Satyanarayana Chava, Founder & CEO of Laurus Labs

“Our mission to provide transformational benefits for cancer patients is greatly strengthened by our ability to work with outstanding companies like Laurus Labs.”

Jagath Reddy Junutula, PhD, Co-founder, President and CEO of Aarvik Therapeutics

The Series Seed 2 round highlights the progress Aarvik has made on its MUTTA™ platform and provides resources to advance its ADC assets for hard-to-treat cancer indications.